# Neumora Therapeutics Appoints Joshua Pinto as CEO


## Key Takeaways

- Neumora Therapeutics has appointed Joshua Pinto, Ph.D., as its new Chief Executive Officer, a move occurring as the company prepares for an Investigational New Drug (IND) filing.
- The company's therapeutic focus is on obesity and neurological disorders, two areas experiencing significant research and development activity, particularly with the recent success of GLP-1 receptor agonists in obesity.
- An IND filing is a critical regulatory step that permits a biotechnology company to initiate human clinical trials for a novel drug candidate, signifying progression towards therapeutic application.
- The leadership transition, particularly with a CEO holding a Ph.D., underscores the scientifically driven decision-making inherent in advancing drug candidates through preclinical and early clinical development stages.
- This executive appointment ahead of a key regulatory milestone like an IND submission may indicate a strategic pivot or an intensified effort to expedite the company's pipeline advancement in its target therapeutic areas.

---

Joshua Pinto, Ph.D., has been appointed chief executive officer of Neumora Therapeutics, a clinical-stage biotechnology company focused on obesity and neurological assets. The leadership change comes as the company prepares for an Investigational New Drug (IND) filing.

Pinto previously served in other leadership roles within the company. His appointment marks a leadership shuffle ahead of a key regulatory milestone.

**Context for the life sciences industry**

Leadership transitions at clinical-stage biotechs often coincide with major development events, such as IND submissions. An IND filing allows a company to begin human clinical trials for a new drug candidate. Neumora’s focus on obesity and neurological conditions places it in two active areas of drug development. Obesity treatments have drawn significant research interest following recent advances in GLP-1 receptor agonists, while neurological disorders remain a high-need field with complex development pathways. A CEO change before an IND may signal strategic realignment or a push to accelerate pipeline progress. The appointment of a leader with a Ph.D. background reflects the scientific nature of the decision-making required at this stage.

Source: [original report](https://www.fiercebiotech.com/biotech/chutes-ladders-neumora-shuffles-leadership-ahead-ind)

## Related Clinical & Scientific Guides

* [define tissue biology](/blog/news/define-tissue-biology)
* [definition tissue biology](/blog/news/definition-tissue-biology)
* [fierce biotech](/blog/news/fierce-biotech)